These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 22996229)

  • 1. Possible pulmonary cryptococcosis in a patient with Crohn's disease during anti-tumor necrosis factor-alpha treatment: a case report and literature review.
    Takazono T; Izumikawa K; Yoshioka S; Matsuo N; Yamakawa M; Suyama N; Kohno S
    Jpn J Infect Dis; 2012; 65(5):461-4. PubMed ID: 22996229
    [No Abstract]   [Full Text] [Related]  

  • 2. Asymptomatic pulmonary cryptococcosis in a patient with Crohn's disease on infliximab: case report.
    Hirai F; Matsui T; Ishibashi Y; Higashi D; Futami K; Haraoka S; Iwashita A
    Inflamm Bowel Dis; 2011 Jul; 17(7):1637-8. PubMed ID: 21674724
    [No Abstract]   [Full Text] [Related]  

  • 3. Late onset of Crohn’s disease in familial Mediterranean fever: the necessity of anti-TNF treatment.
    Kosmidou M; Mpolotsis V; Christou L; Tsianos EV
    J Dig Dis; 2014 Feb; 15(2):102-4. PubMed ID: 24734305
    [No Abstract]   [Full Text] [Related]  

  • 4. Infliximab-induced psoriasis during therapy for Crohn's disease.
    Steinwurz F; Denadai R; Saad-Hossne R; Queiroz ML; Teixeira FV; Romiti R
    J Crohns Colitis; 2012 Jun; 6(5):610-6. PubMed ID: 22398095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary biliary cirrhosis developing in a patient with Crohn's disease during the course of infliximab treatment: the first case in the literature.
    Sisman G; Erzin Y; Bal K
    J Crohns Colitis; 2013 Oct; 7(9):e397-8. PubMed ID: 23583098
    [No Abstract]   [Full Text] [Related]  

  • 6. Stopping anti-TNF agents in patients with Crohn's disease in remission: is it a feasible long-term strategy?
    Sorrentino D; Nash P; Viladomiu M; Hontecillas R; Bassaganya-Riera J
    Inflamm Bowel Dis; 2014 Apr; 20(4):757-66. PubMed ID: 24572206
    [No Abstract]   [Full Text] [Related]  

  • 7. Anti-TNF-α therapy for renal amyloid as a complication of Crohn's disease.
    Blackmur JP; Chapman FA; Bellamy CO; Save V; Plevris JN; Shand AG; Whitworth C; Dhaun N
    QJM; 2014 Jan; 107(1):57-9. PubMed ID: 23681221
    [No Abstract]   [Full Text] [Related]  

  • 8. Relapsed Pulmonary Cryptococcosis during Tumor Necrosis Factor α Inhibitor Treatment.
    Takazono T; Sawai T; Tashiro M; Saijo T; Yamamoto K; Imamura Y; Miyazaki T; Suyama N; Izumikawa K; Kakeya H; Yanagihara K; Mukae H; Kohno S
    Intern Med; 2016; 55(19):2877-2880. PubMed ID: 27725552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transcending conventional therapies: the role of biologic and other novel therapies.
    Sandborn WJ
    Inflamm Bowel Dis; 2001 May; 7 Suppl 1():S9-16. PubMed ID: 11380043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pulmonary cryptococcosis in a patient with Crohn's disease treated with prednisone, azathioprine and adalimumab: exposure to chicken manure as a source of contamination.
    Fraison JB; Guilpain P; Schiffmann A; Veyrac M; Le Moing V; Rispail P; Le Quellec A
    J Crohns Colitis; 2013 Feb; 7(1):e11-4. PubMed ID: 22647638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
    Magro F; Portela F
    BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pericarditis as a complication of infliximab therapy in Crohn's disease.
    Burke JP; Kelleher B; Ramadan S; Quinlan M; Sugrue D; O'Donovan MA
    Inflamm Bowel Dis; 2008 Mar; 14(3):428-9. PubMed ID: 17924565
    [No Abstract]   [Full Text] [Related]  

  • 13. Infliximab-associated psoriasis in children with Crohn's disease may require withdrawal of anti-tumor necrosis factor therapy.
    Broge T; Nguyen N; Sacks A; Davis M
    Inflamm Bowel Dis; 2013 Apr; 19(5):E75-7. PubMed ID: 23435403
    [No Abstract]   [Full Text] [Related]  

  • 14. Salt ageusia in a patient with Crohn's disease treated with tumor necrosis factor antagonists.
    Collet S; Rombaux P; Rahier JF
    Inflamm Bowel Dis; 2013 Apr; 19(5):E73-4. PubMed ID: 23407044
    [No Abstract]   [Full Text] [Related]  

  • 15. Treatment of Crohn's disease patients with infliximab is detrimental for the survival of Mycobacterium avium ssp. paratuberculosis within macrophages and shows a remarkable decrease in the immunogenicity of mycobacterial proteins.
    Bach H; Rosenfeld G; Bressler B
    J Crohns Colitis; 2012 Jun; 6(5):628-9. PubMed ID: 22398081
    [No Abstract]   [Full Text] [Related]  

  • 16. Association of ankylosing spondylitis and Crohn's disease successfully treated with infliximab.
    Rebelo A; Leite S; Cotter J
    BioDrugs; 2010 Dec; 24 Suppl 1():37-9. PubMed ID: 21175236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Inhibitors of TNFalpha].
    Brousse C
    Rev Med Interne; 2003 Feb; 24(2):123-6. PubMed ID: 12650894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Crohn's disease: future anti-tumor necrosis factor therapies beyond infliximab.
    Korzenik JR
    Gastroenterol Clin North Am; 2004 Jun; 33(2):285-301, ix. PubMed ID: 15177539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimizing anti-tumor necrosis factor strategies in inflammatory bowel disease.
    Sandborn WJ
    Curr Gastroenterol Rep; 2003 Dec; 5(6):501-5. PubMed ID: 14602060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What is the importance of anti-TNF agents in the treatment of luminal (inflammatory type) Crohn's disease?
    Kabaçam G; Törüner M
    Turk J Gastroenterol; 2010 Mar; 21(1):107-12. PubMed ID: 20552736
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.